Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The DARK Side of MSL-ing-What No One Tells YOU
Summary
In this episode, Kirsten Gurtowsky shares her experiences and insights as a Medical Science Liaison. She discusses her career journey, highlighting the balance and flexibility required in the MSL role, as well as the challenges faced. Kirsten delves into the importance of building strong relationships with Key Opinion Leaders and offers strategies for successful networking and engagement. She also provides guidance for aspiring MSLs, drawing on her professional experiences. The episode concludes with Kirsten sharing her excitement and goals for the upcoming year, followed by expressions of appreciation.
Kirsten Gurtowsky, Medical Science Liaison with Novartis, discusses the dark side of being an MSL and what you may not be aware of
Kirsten shares….
π What she LOVES about being an MSL
π What some of the main frustrations are for MSLs
π The challenges of travel and uncertainty
π The frustrations that come with paperwork and metrics
π Her insights and predictions for 2024
Medical Science Liaison, Key Opinion Leaders, career journey, challenges faced, successful networking
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary